HRS-5632

HRS-5632 has been studied in 1 paper since 2026: 1 trial in people; 1 in the past year. The newest paper, Nov 2, 2026: “Safety, Tolerability, and Lipoprotein(a)-Lowering Effect of HRS-5632, an Extended Long-Acting Small Interfering RNA Targeting Lipoprotein(a): A Randomized, Double-Blind, First-in-Human Study”.

Intervention

1 paper studies it1 findingUpdated

1 new paper in 30 daysSee all 1 papers on HRS-5632

At a glance

The findings reach people, from one lab or study. 1 lab in 1 country.

“HRS-5632 at 10 mg or higher could reduce lipoprotein(a) by ≥90%.”
Safety, Tolerability, and Lipoprotein(a)-Lowering Effect of HRS-5632, an Extended Long-Acting Small Interfering RNA Targeting Lipoprotein(a): A Randomized, Double-Blind, First-in-Human StudyAHA Scientific Sessions 2026 abstract2026doi:10.1161/circ.154.suppl_1.6307
Humans: a single group. Cells, worms or flies and mice: nothing yet.
  • 1 lab in 1 country
  • 1 of 1 finding with company ties
  • Human trial1

Studies in people

1 study gave HRS-5632 to people and measured what changed.

What changedDesignPeopleSource

down: Decreases lipoprotein≥90% reduction at ≥10 mg; at week 48, ≥90% reduction in 87.5% and 100.0% of the 200 mg and 400 mg cohorts, respectively

Randomized trialapproximately one year at 200 mg or 400 mg40 people18 to 55 yearsMidlife adults; Healthy participants with lipoprotein(a) ≥75 nmol/LAHA Scientific Sessions 2026 abstract, Nov 2, 2026

What did studies of HRS-5632 find?

1

Studies of HRS-5632 measured one outcome, lipoprotein.

Lipoprotein

downin humans1

1 study
  1. HRS-5632 decreases lipoprotein in humans (Healthy participants with lipoprotein(a) ≥75 nmol/L) (≥90% reduction at ≥10 mg; at week 48, ≥90% reduction in 87.5% and 100.0% of the 200 mg and 400 mg cohorts, respectively).

    “HRS-5632 at 10 mg or higher could reduce lipoprotein(a) by ≥90%.”

    Human trialHealthy participants with lipoprotein(a) ≥75 nmol/L10 mg or higherapproximately one year at 200 mg or 400 mgn = 40

    Safety, Tolerability, and Lipoprotein(a)-Lowering Effect of HRS-5632, an Extended Long-Acting Small Interfering RNA Targeting Lipoprotein(a): A Randomized, Double-Blind, First-in-Human Study

    AHA Scientific Sessions 2026 abstract

More on Lipoprotein

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 0Nov 2026: 11 paper in 12 months